EQRx, Inc.

• The Janus Kinase (JAK) inhibitor pipeline is actively being developed by multiple companies, showing promise in treating various autoimmune and inflammatory diseases. • Key companies such as Incyte, AbbVie, and Bristol Myers Squibb are advancing JAK inhibitor therapies through clinical trials and regulatory submissions. • Emerging therapies like povorcitinib, upadacitinib, and deucravacitinib have demonstrated efficacy in treating conditions like hidradenitis suppurativa, axial spondyloarthritis, and plaque psoriasis. • The JAK inhibitor market is driven by the rising prevalence of chronic diseases and substantial investments in research and development, offering targeted treatment approaches.

• RMC-6236 demonstrates encouraging anti-tumor activity across multiple RAS variants (G12D, G12V, and G12R), with a 38% objective response rate in non-small cell lung cancer. • RMC-6291 shows a 50% objective response rate in lung cancer patients who progressed on prior KRAS G12C inhibitors, suggesting clinically meaningful differentiation. • Revolution Medicines anticipates initiating a pivotal Phase 3 trial for RMC-6236 in second-line RAS-mutant non-small cell lung cancer in 2024. • The company expects to acquire EQRx, gaining $1.1 billion in net capital to support the late-stage development of its RAS(ON) inhibitor pipeline.